RNA, U6 small nuclear 2Genealiases: RNU6B · RP104 · U6-2
Q-omics provides the consensus-scored RNU6-2 profile across patient tissues and cancer cell-line models. RNU6-2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNU6-2 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, RNU6-2 RNA expression shows 7,193 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, THCA, and ACC as cancer lineages where RNU6-2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6-2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6-2 survival associations across molecular data types. RNU6-2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6-2 RNA expression–survival associations across cancer types. High RNU6-2 expression shows unfavorable associations in MESO, KIRC, LIHC and KICH, but favorable associations in BLCA and ESCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for RNU6-2 RNA expression.
This table summarizes RNU6-2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6-2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6-2 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, UCEC, CHOL and READ. The THCA box plot shows higher RNU6-2 RNA expression in normal versus tumor tissue (log2 FC = −2.182, t-test p < 0.001).
This table shows molecular features associated with RNU6-2 in patient tissues and cancer cell lines. In patient samples, RNU6-2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
